While IPOs in the biotech bull run have been leaving some money on the table for new investors in the aftermarket, the reception for cancer sequencing company Foundation Medicine Inc. was over the top.

On its first day of trading last Wednesday, the share price nearly doubled and sent the biotech's market cap to almost $1 billion.